Page last updated: 2024-08-26

paxilline and MEA 2a

paxilline has been researched along with MEA 2a in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	1 (100.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Bocciardi, R; Borrello, MG; Bourget, I; Fischer, S; Mograbi, B; Pasini, B; Pierotti, MA; Romeo, G; Rossi, B	1

Other Studies

1 other study(ies) available for paxilline and MEA 2a

Article	Year
The multiple endocrine neoplasia type 2B point mutation switches the specificity of the Ret tyrosine kinase towards cellular substrates that are susceptible to interact with Crk and Nck. Oncogene, 1997, Nov-06, Volume: 15, Issue:19 Topics: Adaptor Proteins, Signal Transducing; Animals; COS Cells; Cytoskeletal Proteins; Drosophila Proteins; Multiple Endocrine Neoplasia Type 2a; Oncogene Proteins; Paxillin; Phosphoproteins; Point Mutation; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-crk; Proto-Oncogene Proteins c-ret; Receptor Protein-Tyrosine Kinases; Signal Transduction; src Homology Domains; Substrate Specificity	1997

Article

Year

The multiple endocrine neoplasia type 2B point mutation switches the specificity of the Ret tyrosine kinase towards cellular substrates that are susceptible to interact with Crk and Nck.

Oncogene, 1997, Nov-06, Volume: 15, Issue:19

Topics: Adaptor Proteins, Signal Transducing; Animals; COS Cells; Cytoskeletal Proteins; Drosophila Proteins; Multiple Endocrine Neoplasia Type 2a; Oncogene Proteins; Paxillin; Phosphoproteins; Point Mutation; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-crk; Proto-Oncogene Proteins c-ret; Receptor Protein-Tyrosine Kinases; Signal Transduction; src Homology Domains; Substrate Specificity

1997